Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22338201 | 0.75 | EGFR (0.32) | EGFR | |
| SCHEMBL30228836 | 0.74 | PIK3CA (0.47) | KMOPIK3CAEGFRFAAHPDK1 | |
| SCHEMBL30228789 | 0.67 | EGFR (0.33) | KMOPIK3CAEGFR | |
| SCHEMBL25092699 | 0.67 | EGFR (0.33) | KMOPIK3CAEGFR | |
| SCHEMBL18754183 | 0.63 | MCHR1 (0.36) | — | |
| SCHEMBL20068632 | 0.63 | FAAH (0.31) | FAAH | |
| SCHEMBL15504648 | 0.63 | LOX (0.38) | — | |
| SCHEMBL20705128 | 0.63 | PDK1 (0.47) | KMOPIK3CAPDK1PDK2PDK3 | |
| SCHEMBL30229229 | 0.63 | PIK3CA (0.31) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL21202793 | 0.62 | PDK2 (0.39) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | KMO 4380/4885PIK3CA 1773/4885EGFR 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.